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Background: Plerixafor (PFX) mobilizes CD34+ cells
into circulation by disrupting the CXCR4 binding of the
hematopoietic stem cell in its bone marrow niche.
Study design and Methods: in the prospective
HOVON-107 study (www.hovon.nl) 23 allogeneic HLA–
identical sibling donors received one or two
subcutaneous (sc) injections of plerixafor 0.320 mg/kg.
The primary endpoint, was deﬁned as feasibility to
mobilize a minimum of 2.0 x106 CD34+ cells/kg recipient
weight obtained by leukopheresis in at least 90% of the
donors.
Results: median 3.3 x 106 CD34+ cells/kg (1.9-6.5)
were collected after 1 (n=12) or 2 (n=10) sc injections of
PFX. Side effects occurred in 15/23 (65%) donors: most
were grade 1-2; in 5 donors grade 3 and all resolved. All
grafts were directly transplanted. Compared to 10 grafts
obtained with G-CSF the number of CD34+ cells was 2.4
fold lower but the percentage of phenotypically most
immature CD34+ subset was higher (31% vs 15%). The
total number of CD3+ cells in the graft seemed higher
after PFX-mobilization, but CD4/CD 8 ratios, and
frequencies of Th2, Th17 and regulatory T-cells or NK
cells were comparable. All patients engrafted and no
increase in incidence or severity of acute or chronic graft
versus host disease was observed.
Conclusion: stem cell mobilization with sc PFX 0.320
mg/kg in allogeneic sibling donors is feasible with limited
toxicity for donors. 14 allogeneic donors were mobilized
with PFX 0.320 mg intravenously according to the same
protocol. Due to the limited numbers, these results are in
the supplementary section.
T
he mobilization of hematopoietic stem and pro-
genitor cells (HSPCs) in allogeneic human leuko-
cyte antigen (HLA)-identical sibling donors with
subcutaneous (SC) injections of granulocyte-
colony stimulating factor (G-CSF) is standard practice.1
In most donors, this results in a sufﬁcient number of CD34+
cells for subsequent transplantation. However, it requires
the administration of one to two daily SC injections for a
period of 4 to 6 days, and side effects of G-CSF have been
ABBREVIATIONS: ANC = absolute neutrophil count; CI =
conﬁdence interval; CXCR4 = chemokine receptor 4; G-CSF =
granulocyte-colony stimulating factor; GvHD = graft-versus-host
disease; HLA = human leukocyte antigen; HSPCs = hematopoietic
stem and progenitor cells; IV = intravenous; NK = natural killer;
PXF = plerixafor; SC = subcutaneous.
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reported in the majority of healthy donors with the follow-
ing median frequencies: bone pain, 70% to 86%; headache,
40%; myalgias, 36%; fatigue, 20%; nausea/vomiting, 10%;
and fever, 3%.2 Often, this requires the use of medication
such as paracetamol and causes discomfort, with an effect
on daily life and/or work. Administration of G-CSF can
induce a transient increase in spleen size; in some donors, a
rupture of the spleen has been reported.2–4 Considering
this, another way of effective mobilization with fewer side
effects could be of advantage.
HSPCs express the chemokine receptor 4 (CXCR4).
Plerixafor (PXF) is a small bicyclam molecule that reversibly
binds and blocks CXCR4. This results in inhibition of the
binding with its ligand stroma cell–derived factor-1, also
known as C-X-C motif chemokine-12, and causes the direct
release of HSPCs from their niches in the bone marrow
stroma into the circulation.5 Two randomized controlled
Phase III trials in patients with multiple myeloma and non-
Hodgkin lymphoma showed that addition of PXF to G-CSF
led to signiﬁcantly higher numbers of CD34+ cells in ﬁrst
mobilization procedures.6,7 Several compassionate use pro-
grams in the United States and Europe emphasized the
favorable role of PXF in patients with mobilization failure
after G-CSF, showing success rates of 60% to 80% with PXF.
These studies resulted in approval by the Food and Drug
Administration and European Medicines Agency of PXF in
combination with G-CSF for its use in patients who fail to
mobilize autologous stem cells.8 However, data on the use
of PXF in allogeneic stem cell donors are limited.
In the study of Devine et al.,9 25 sibling donors
received 0.24 mg/kg PXF SC. At least 2× 106/kg CD34+ cells
were collected in 22 of 24 donors after one (16 of 24) or two
(6 of 8) SC injections. One donor mobilized 1.9 × 106/kg,
which was used for transplant with successful engraftment.
Following transplantation after myeloablative conditioning
(20 patients), engraftment was rapid and complete in all
patients with median time to absolute neutrophil count
(ANC) greater than 0.5 × 109/L of 10 days (range,
8–13 days) and median time to platelet counts greater than
50 × 109/L of 18 days (12–32). Most donors observed only
mild side effects (Grade 1), that were reported directly after
administration of PXF: lightheadedness (40%); nausea,
bloating, or ﬂatulence (36%); injection site discomfort, warm
sensation (28%); perioral paresthesias, loose stools, or dia-
phoresis (20%); and headache (16%). One donor com-
plained about Grade 2 pain at the injection site. All
toxicities resolved in a few days. Although a high number of
CD3+ and CD4+ T cells were present in grafts mobilized
with PXF, this was not associated with a high incidence of
graft-versus-host disease (GvHD) in the transplanted
patients. The intravenous (IV) administration of PXF
0.320 mg/kg followed by leukapheresis 4 hours later
resulted in the collection of at least 2 × 106 CD34+ cells in
19/29 HLA-identical sibling donors.10 In seven donors, this
target was reached after a second IV injection.
Adverse effects after IV administration of PXF seemed
comparable to the side effects after SC injection. Grade
1 abdominal discomfort (30%) and bradycardia (30%) were
most common. No Grade 3 or 4 adverse effects occurred.
PXF has not been studied prospectively in daily practice of
donor mobilization and subsequent allogeneic transplant.
Therefore, the primary aim of the current study was to
assess the feasibility and side effects of PXF 0.320 mg/kg SC
to mobilize sufﬁcient HSPCs in HLA-identical sibling donors
and to determine engraftment in the transplanted patients.
Also chimerism, immune reconstitution, and incidence of
GvHD were analyzed. Finally, kinetics of CD34 cell mobili-
zation as well as the composition of the stem cell graft with
respect to numbers of HSPCs, T cells, T-cell subsets, and
regulatory T cells were investigated.
MATERIALS AND METHODS
The present HOVON-107 study (www.hovon.nl) started as a
Phase 2 prospective, randomized study in allogeneic HLA-
identical sibling donors and patients. The primary endpoint
was the feasibility of PXF 0.320 mg/kg SC (arm A) or IV
(arm B) to mobilize at least 2.0 × 106 CD34+ cells/kg
receiver weight for transplant. Feasibility was deﬁned as a
minimum of 2.0 × 106/kg CD34+ cells after one or two
doses of PXF and subsequent leukapheresis in at least 90%
of the donors. Interim analysis after 10 donors in each of
the two arms concluded it was safe to continue. Unfortu-
nately, accrual was not as expected. Moreover, it appeared
that IV administration followed by leukapheresis 4 hours
later resulted in very long hours for donors, collection cen-
ters, and stem cell laboratories. For both reasons, it was
decided to close the IV arm and to continue with the SC
arm only. The current paper describes the characteristics
and results for 23 donor/patient pairs (arm A). The number
of 14 IV donors and patients (arm B) is considered too small
to conclude about feasibility of IV PXF. Therefore, the
results for this group are found in Appendix S1, available as
supporting information in the online version of this paper.
For the ﬂow diagram of donors, see Fig. 1.
After written informed consent, donors received PXF
0.320 mg/kg as a single SC injection 9 hours before the
planned stem cell collection. In case the absolute number of
CD34+ cells in the harvest was less than 2.0 × 106/kg recipi-
ent weight, a second injection of PXF was administered and
stem cells collected the following day. The leukapheresis
procedure should process 15 L of peripheral blood. It was
advised to transplant grafts containing 1 × 106 CD34+ cells/
kg or greater after two mobilizations. In case less than 1 ×
106 CD34+ cells/kg were collected after two mobilizations, it
was strongly advised that bone marrow cells should be har-
vested from the donor the following day by multiple punc-
tures under general anesthesia.
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Inclusion criteria for donors were age 18 to 60 years
inclusive; hematologic parameters within normal limits; and
capability of undergoing leukapheresis and adequate venous
access. All donors consented to insertion of a peripheral
venous catheter and bone marrow collection if necessary.
A negative pregnancy test at study entry for women of child-
bearing potential was mandatory. Also, all donors agreed to
use adequate contraception during the mobilization period
and up to 3 months after last dose of PXF. In addition,
donors should fulﬁll standard criteria for donor eligibility.
Donors with unstable hypertension requiring more than one
medication were excluded. Ultrasonography of the spleen
was performed before the administration of PXF and
repeated directly after the stem cell collection. For donor
characteristics see Table 1A.
Patients were included after written informed consent.
Indication for allogeneic stem cell transplant was determined
by each participating center according to local criteria. Age
for inclusion was 18 to 65 years inclusive. For patients with a
myelodysplasia with International Prognostic Scoring System
score of 1.5 or greater, acute myeloid or lymphatic leukemia,
a ﬁrst complete remission was required. For all patients,
the World Health Organization performance score should be
2 or less and life expectancy greater than 3 months. Trans-
plants and GvHD prophylaxis were performed according to
institutional guidelines. For patient characteristics see
Table 1B. The absolute number of viable CD34+ cells was
determined by ﬂow cytometry using a stem cell enumeration
kit (Beckman Coulter) according to the manufacturer’s
instructions and the single platform ﬂow cytometry Interna-
tional Society of Hematotherapy and Graft Engineering
gating strategy in blood of the donor obtained just before
administration of PXF; at 2, 4, and 6 hours after PXF adminis-
tration; just before initiating apheresis; and after 5, 10, and
ﬁnally 15 L of blood had been processed.11,12
During apheresis, the number of CD34+ cells in the
graft was also determined after 5, 10, and 15 L processed
blood volume. The composition of PXF-mobilized hemato-
poietic progenitor cells, apheresis products obtained after
the ﬁrst stem cell collection, was evaluated by ﬂow cytome-
try. The absolute number of CD34+ cells was determined as
described above. To assess the frequency of lin−CD38low/
CD45RA‑/CD90+ phenotypic hematopoietic stem cells and
CD19+ pre−/pro B cells within the CD34+ population, cells
were stained with lineage ﬂuorescein isothiocyanate,
Off Protocol n=23
- normal completion n=23
Off Protocol n=1
- patient died ,no mobil. n=1
R
Arm B: IV
N = 14*
Arm A: SC
N = 24
Plerixafor SC
N = 23
1 cycle n=13
2 cycles n=10
Plerixafor IV
N=14
1 cycle n= 9
2 cycles n= 5
Off Protocol n=14
- normal completion n=13
- toxicity n=1
Fig. 1. Flow diagram of the inclusion of donors/patients in the HOVON-107 study.
TABLE 1A Donor characteristics
n = 23
Age [y], median (range) 47 (24–60)
Male/female 16/7
WHO 0 23
Hb [mmol/L], median (range) 9.0 (7.7-10.7)
WBC [× 109/L], median (range) 6.1 (4.0–10.7)
Platelets [× 109/L], median (range) 226 (130–318)
Spleen size [cm], median (range) 11 (7–13) (n = 21)
TABLE 1B Patient characteristics
n = 23
Age 50 (21–64)
Male/female 17/6
WHO 0 9
WHO 1 10
WHO 2 4
AML/MDS 9
ALL 4
MM 4
Lymphoma 4
CLL 2
Stage of disease at transplant
CR 12
PR 7
SD 4
Nonmyeloablative SCT 17
Myeloablative SCT 6
ALL = acute lymphoblastic leukemia; AML = acute myeloid leuke-
mia; CLL = chronic lymphocytic leukemia; CR = complete remis-
sion; Hb = hemoglobin; MDS = myelodysplastic syndrome; MM =
Multiple Myeloma; PR = Partial remission; SD = Stable disease;
SCT = stem cell transplant; WHO = World Health Organization.
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CD34-Pe-Cy7, CD19-APC, CD38-PE-Cy5, CD45RA-APC-H7,
and CD90-PE. The absolute number of CD3+, CD3+/CD4+,
CD3+/CD8+, CD3−/CD16+/CD56+, and CD19+ cells in the
graft was assessed using four-color direct immunoﬂuores-
cence reagent kits (Becton Dickinson). The frequency of T
helper cells (Th1, Th2, Th17) within the CD4+ T cells was
assessed using a phenotyping kit (Human Th1/Th2/Th17
Phenotyping kit, Becton Dickinson) according to the manu-
facturer’s instructions. The frequency of Foxp3+ Treg within
CD4+ cells was analyzed by intracellular staining using an
antihuman staining set (Foxp3, e-Bioscience) after ﬁxation
and permeabilization of peripheral blood cells according to
the manufacturer’s instructions.
Results were compared to 10 G-CSF-mobilized hemato-
poietic progenitor cells, apheresis products obtained from
healthy adult sibling donors previously mobilized with G-CSF
10 μg/kg during 5 days. For chimerism analysis, DNA was iso-
lated from peripheral blood cells, peripheral blood T cells
and bone marrow cells using a blood genomic prep mini spin
kit (Illustra, GE Healthcare) according to the manufacturer’s
instruction. T lymphocytes were puriﬁed from peripheral
blood using a human whole blood CD3 positive selection kit
(STEMCELL Technologies, Inc.) according to the manufac-
turer’s instructions. Chimerism analysis was performed by
polymerase chain reaction ampliﬁcation of ﬁve informative
STR loci at 3, 6, 12, and 24 months after transplantation. The
resulting labeled polymerase chain reaction products were
size fractionated by capillary electrophoresis and quantiﬁed.
In the patients, immunological reconstitution was
determined at 3, 6, and 12 months after transplantation.
Absolute numbers of T, B, and natural killer (NK) cells as
well as the CD4 and CD8 subpopulations of T cells in
peripheral blood were determined by a single-platform ﬂow
cytometric assay using four-color direct immunoﬂuores-
cence reagent kits (Becton Dickinson) and ﬂuoropheres to
determine absolute counts on a ﬂow cytometer (Beckman
Coulter). All ﬂow cytometric analyses were performed using
a cell analyzer (FACSCalibur, Becton Dickinson). Flow cyto-
metric data were collected and analyzed using computer
software (CELLQuest, Becton Dickinson).
Statistical analysis
The study was originally designed as a randomized, multi-
center phase II trial with two treatment arms,
i.e., mobilization with either PXF SC (arm A) or IV (arm B).
The aim of the study was to assess the feasibility of each of
the two arms separately, as deﬁned before. For each treat-
ment arm, the optimal Simon 2-stage design was applied.13
However, a formal comparison between the two arms would
not be applied. In each of the two arms, a true percentage of
70% successful harvests would be considered insufﬁcient,
while 90% or more would be desirable and warrant further
investigation of the arm(s). With α = 0.10 and β = 0.20, a
sample size of 28 patients per arm would be required, with
an interim analysis after the ﬁrst 9 donors. At the ﬁnal analy-
sis at least 23 of 28 successful had to be observed in one arm
to conclude that the arm would be feasible. Because of slow
accrual, the trial was amended to continue only with arm A.
The estimated rate of donors with 2.0 × 106 or more
CD34+ cells/kg recipient weight after one or two harvests
would be calculated along with the 90% conﬁdence interval
(CI). Continuous variables were summarized by median
and range. Adverse events were scored according to the
National Cancer Institute’s Common Terminology Criteria
for Adverse Events, version 4.0, separately for donors and
patients. Progression-free and overall survival rates were
estimated by the Kaplan–Meier method, and 95% CIs were
constructed. Kaplan–Meier survival curves were generated
to illustrate progression-free survival and overall survival.
RESULTS
The results for the SC administration of PXF are shown
below. The results for the IV administration are found in
Appendix S1, available as supporting information in the
online version of this paper. Between August 2012 and
January 2017, a total of 24 donors were included in the PXF
SC arm. One donor was not treated because the patient had
already died. For donor characteristics see Table 1. Twenty-
three donors received PXF 0.320 mg/kg SC, median
9.7 hours (range, 8–10.7), before the planned stem cell col-
lection. In 12 donors, this resulted in 2 × 106/kg or more
recipient weight CD34+ cells. In one donor 1.9 × 106/kg
CD34+ cells was considered sufﬁcient for transplant. Ten of
23 donors needed a second SC injection and stem cell col-
lection. Finally, median 3.3 (1.9–6.5) × 106/kg recipient
weight CD34+ cells were collected in all 23 donors and
transplanted. These 23 donors and patients were required
to consider the SC PXF arm feasible. As the primary end-
point had been achieved, it was decided to close the trial.
Side effects related to PXF occurred in 15 of 23 (61%)
donors with the majority Grade 1 or 2 (Table 2). Common
TABLE 2 Adverse events after PXF 0.32 mg/kg SC
Adverse event Grade 1 Grade 2 Grade 3
Clotting during apheresis − − 3
Tingling 4 3 −
Nausea/vomiting 3 3 −
Flulike/fatigue 1 4 1
Headache 3 − −
Abdominal discomfort/diarrhea 1 2 −
Decreased platelets − 3 1
Dizziness 2 1 −
Flushing 1 1 −
Left ﬂank pain 1 − −
Hypotension − 1 −
Arm pain 1 −
Adverse events were scored according to the National Cancer
Institute’s Common Terminology Criteria for Adverse Events,
version 4.0.
4 TRANSFUSION
DE GREEF ET AL.
Terminology Criteria for Adverse Events Grade 3 side effects
were clotting during the leukapheresis procedure in two
donors, decrease of platelets in one donor, and fatigue after
the mobilization procedure in one donor. Grade 3 hypokale-
mia and syncope were observed each in one donor but con-
sidered not related. All side effects resolved. No Grade
4 adverse effects were reported. Stem cell collection was
performed by leukapheresis with an apheresis system
(Spectra Optia, Terumo BCT) in 18 donors and Cobe Spec-
tra (Terumo BCT) in 5 donors. The volume of processed
blood was median 14.6 (9.1–23.1) L. In 10 donors in which
a second collection was performed, a median of 13.4
(7.0–23.1) L of blood was processed. One donor needed an
inguinal central catheter due to clotting during the ﬁrst pro-
cedure. Spleen sizes in 23 donors determined by ultrasound
were found to be within normal range at the start: median
11 (10–12) cm, and within similar range the day after PXF:
median 11 (10–12) cm. The steady state CD34+ cell number
in peripheral blood before the ﬁrst PXF administration was
low, that is, median 3 (1–5) × 106 CD34+ cells/L. At 2 hours
after SC administration of PXF, an increase of CD34+ cells
in blood was apparent: median 13 (5.9–50) × 106/L. At
4 and 6 hours after PXF the CD34+ cell levels were only
slightly higher: median 20 (9.6–49) × 106/L and median
20 (11–58) × 106/L, respectively.
At the start of stem cell collection, 8 to 11 hours after the
administration of PXF, CD34+ cells in the peripheral blood
were median 26.1 (8.5–71.1) × 106/L (Fig. 2A). During the
apheresis procedure, the numbers of CD34+ cells in the
peripheral blood initially dropped but did not change much
thereafter. After 5 L of processed blood volume, the CD34+
cells were median 18 (10–52) × 106/L; after 10 L, 16 (6.9–46)
× 106/L; and after 15 L, median 15.9 (5.7–47.5) × 106/L. The
amount of CD34+ cells in the grafts after 5, 10, and 15 L of
processed blood volume were median 0.6 (0.2–2.6), 1.4
(0.6–3.4), and 2.1 (1.1–6.6) × 106/kg receiver weight, respec-
tively (Fig. 2B,C). The grafts obtained after a single SC injec-
tion of PXF contained a median of 194 (79–548) × 106 CD34+
cells (Table 3). Within the CD34+ cell population, 31%
showed the phenotype of the primitive hematopoietic stem
cell: (lin− CD34+/CD38low/ CD45RA-/CD90+) and 55% had
the phenotype of the more committed multipotent/common
myeloid progenitor cells (CD34+/CD45RA+/CD90–). A small
percentage of CD34+ cells coexpressed CD19 (2.85%). The
10 G-CSF mobilized grafts contained a median of 438 × 106
(356–840) CD34+ cells, of which 15% were phenotypic hema-
topoietic stem cells and 77% phenotypic multipotent/com-
mon myeloid progenitor cells. The fraction of CD34+/CD19+
cells was 2%. Grafts obtained after PXF mobilization con-
tained more CD3+ cells: median 22.6 (10.6–56.7) × 109 com-
pared to G-CSF (CD3+ cells: median 12.8 (7.6–21) × 109). The
CD4/CD8 ratios were comparable, as well as the frequencies
of IL-4+/ CD4+ Th2 cells; IL-17+/CD4+/Th17 cells and CD4+
/Foxp3+ regulatory T-cells. Also, the numbers of CD3–/CD16
+/CD56+ NK cells were similar both after PXF and G-CSF.
The number of CD19+ B cells in the PXF-mobilized grafts
appeared twice as high as in G-CSF-mobilized grafts.
All 23 patients were directly transplanted with the PXF
mobilized grafts. Conditioning was myeloablative in
6 patients and nonmyeloablative in 17 patients. GvHD pro-
phylaxis was given according to local protocol. One patient
received cyclophosphamide following transplantation. All
patients engrafted and recovered, with ANC greater than 0.5
× 109/L median on Day 17 (0–27) and platelets greater than
50 × 109/L on Day 13 (0–23). Acute GvHD was observed in
Fig. 2. (A) Appearance of CD34+ cells in the peripheral blood
(PB) 2, 4, and 6 hours after SC administration of plerixafor
0.23 mg/kg. (B) CD34+ cells were analyzed at start and during
stem cell apheresis after 5, 10, and 15 L of processed blood
volume in the peripheral blood and (C) in the stem cell graft.
Each box is drawn from the 25th percentile to the 75th
percentile of the CD34+ counts, and the horizontal bar within
the box indicates the median CD34+ count. The lineup from the
top of the box goes to the upper adjacent value.14 The dots
indicate CD34+ counts larger than the upper adjacent value.
[Color ﬁgure can be viewed at wileyonlinelibrary.com]
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6 of 23 patients: 2 patients, Grade 3; 1 patient, Grade 2; and
3 patients, grade 1. One patient died of steroid-refractory
GvHD. Chronic extensive GvHD was present in 7 of
23 patients, and limited GvHD in 3 of 23. The latter involved
liver and mouth in all patients, skin in 3, eyes in 2, and
lungs in 1 patient. At 12 months, it was ongoing in
4 patients. Overall survival and progression-free survival at
12 months were 72% (95% CI, 49%–87%) and 55% (95% CI,
32%–73%). Eight of 23 patients died: 5 because of disease
progression, 2 with infection, and 1 with GvHD. Median
follow-up of patients still alive is 24 months (6–26).
With respect to chimerism at 3 months, 11 of
16 patients with available data showed full donor chimerism
in the peripheral blood. For bone marrow and CD3, this
was found in 13 of 15 and 5 of 14 patients. At 12 months, all
analyzed patients had complete donor hematopoiesis in all
fractions (Table 4). Data on immunologic reconstitution of
16 of 23 transplant recipients showed CD3/CD8 cells and
NK cells at normal range 3 months after transplantation.
Numbers of CD3+ cells, CD3+ /CD4+ cells and CD19+ cells
showed a gradual increase and were within normal range at
12 months (Fig. 3).
DISCUSSION
The current study shows that PXF 0.320 mg/kg SC has activ-
ity as a mobilizing agent in allogeneic HLA-identical sibling
donors: All 23 donors mobilized sufﬁcient CD34+ cells for
transplant after one or two injections. The failure rate of 48%
after the ﬁrst injection is somewhat higher compared to other
studies: Most describe failure rates around 30% to mobilize
at least 2 × 106 CD34+ cells with a single SC or IV injection
PXF (Table 5). As peak CD34+ cells in the blood appeared
higher with a single dose of 0.480 mg/kg PXF IV, it was sug-
gested that this dose might improve the failure rates.15 How-
ever, in this study, no subsequent stem cell collection was
performed. Although the total number of CD34 + cells after
TABLE 3 Composition of the grafts obtained from healthy adult sibling donors
PXF SC %* G-CSF %*
N 23 10
CD34+ × 106 194 (79–548) 438 (356–840)
CD 34+/CD45RA–/CD90+ × 106 49 (4–211) 31.3% 65 (11–200) 15%
CD 34+/CD45RA–/CD90– × 106 133 (20–428) 55% 312 (195–572) 77%
CD34+/CD 19+ 5.1 (1.8–27.6) 2.1 (0.0–4.3)
CD3 × 109 22.6 (10.6–56.7) 12.8 (7.6–21)
CD3/CD4 × 109 14.8 (6.1–30.5) 7.5 (4.3–15.4)
CD3/CD8 × 109 7.2 (2.7–22.1) 3.8 (2.0–6.0)
CD 4/8 ratio 1.7 (1.1–5.2) 1.6 (1.0–5.5)
CD3–/CD16+/CD56+ × 109 1.9 (0.5–6.90) 1.3 (0.5–2.9)
CD19+ × 109 6.3 (2.7–18.1) 3.1 (1.9–4.5)
Fox P3, % 6.3 (2.7–10.4) 5.8 (2.6–10.9)
Th1,% 24.4 (3.0–40.7) 16.6 (2.5–27.5)
Th2, % 2.5 (0.4–7.5) 2.3 (0.5–4.4)
Th17, % 1.3 (0.2–25.9) 1.4 (0.2–5.0)
23 PXF mobilized grafts were obtained after a single injection of 0.32 mg/kg SC PXF. Ten G-CSF mobilized grafts were obtained after injection
of G-CSF 2 × 5 μg/kg SC during 5 days.
* Percentage of total number of CD34+ cells.
G-CSF = granulocyte-colony stimulating factor; N = number; PXF = plerixafor; SC = subcutaneous; Th = T helper cell.
TABLE 4 Chimerism in peripheral blood (PB), bone marrow (BM), and CD3 selected cells at 3, 6, and 12 months after
transplant
N PB %* BM %* CD3 %*
3 months 20 Complete 13 81% 13 87% 6 40%
Incomplete 3 2 9
nd 4 5 5
6 months 17 Complete 11 100% 10 91% 9 75%
Incomplete 0 1 3
nd 6 6 5
12 months 11 Complete 4 100% 3 100% 5 100%
Incomplete 0 0 0
nd 7 8 6
N = number of patients that were still progression free and alive at each of the time points. Complete ≥95% donor cells. Incomplete <95% donor
cells.
* Percentage of patients with available data.
nd = not done
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PXF was 2.4-fold lower compared to G-CSF, the percentage
of lin–CD34+/CD38low/CD45RA–/CD90+ cells was almost
twice as high (31% vs. 15%). Therefore, PXF preferentially
mobilizes the most primitive phenotypic HSC.16
Recent studies showed also that PXF seems to mobilize
a more primitive unique population of CD34dim/CD45 RA+
cells that appeared to be plasmacytoid progenitor cells16–18
and CD34dim/CD45RA+/ CD123++ plasmacytoid dendritic
cell precursors.10 The meaning of this ﬁnding with respect
to immune function in the transplant recipient is not known
yet. In our study, we did not look speciﬁcally at these plas-
macytoid dendritic cells. Our study is the largest study in
the allogeneic setting that directly transplanted the PXF
mobilized grafts, resulting in quick engraftment both for
neutrophils and platelets. This holds also for the grafts
obtained with IV PXF. Although chimerism data are limited,
they suggest complete donor hematopoiesis in all fractions
at 12 months. In accordance with previous reports, grafts
obtained with PXF contained more CD3+ cells.9,10
Alloreactive CD4+ T cells and their cytokines are asso-
ciated with acute GvHD but their relation with chronic
GvHD is less straightforward.19,20 For the latter, both regula-
tory T cells and CD19 + B cells and T-follicular helper cells
are believed to play a role.21,22 We did not look at the
T-follicular helper cells but the frequencies of regulatory
T cells in the grafts were similar with PXF or G-CSF. The
occurrence of acute (2 patients grade 3) and chronic exten-
sive GvHd at 120 days (7 of 17 patients at risk [30%])appears
to be as expected in the setting of non-T-cell–depleted
transplantation.23–26 The immunologic reconstitution
improved gradually and was almost within normal range
12 months after transplantation. For comparison, no differ-
ences in absolute numbers in blood of CD3, CD3/CD4,
CD3/CD8, and NK cells were observed 3, 6, and 12 months
after transplantation in 20 patients who received G-CSF
mobilized HSCs in the same period (data not shown). This
is in accordance with earlier reports.27 Numbers of CD19+
cells appeared higher in PXF mobilized grafts. Interestingly,
TABLE 5 Studies with plerixafor in allogeneic donors
Study
reference/year n Dose mg/kg
Failure
after 1 gift
Proc.
Vol. ltrs.
CD34 × 106/kg*
Med (range)
Direct
trans-plant Eval pts
Engraftment median day
(range)
Devine9 2008 25 0.240 SC 33% 20 2.9
(1.2–6.3)
No 20 ANC 10 (8–13)†
Plt 18 (12–32)‡
Gattillo28 2015 10 0.35 SC||
(0.24–0.47)
15–20 2.8
(1.1–4.3)
yes 10 ANC 17 (15–25)
Plt 18 (10–101)§
Schroeder10 2017 21 0.240 SC 33% 20 3.5
(1.9–19.7)
No 18 ANC 10 (9–12)†
Plt 33 (19–70)‡
Schroeder10 2017 29 0.320 IV¶ 34% 17.9 (3.7–20) 2.9
(2.0–9.7)
No 33 ANC 14 (11–27)**
Plt 25 (15–219)‡,**
H-107 study 2018 23 0.320 SC 48% 14.6 (9.1–23.1) 3.3
(1.9–6.5)
Yes 23 ANC 17 (0–27)
Plt 13 (0–23)‡
* Recipient weight (kg).
† G-CSF started on day 1.
‡ Engraftment deﬁned as: ANC > 0.5x 109; and platelet >50 x 109.
§ Engraftment deﬁned as: ANC > 0.5x 109; and platelet >20 x 109.
|| Plerixafor was administered to eight donors with inadequate graft after G-CSF.
¶ After the ﬁrst dose escalation part of the study, a second gift plerixafor was administered after a wash out of 4 days.
** GvHD prophylaxis included methotrexate.
ANC = absolute neutrophil count; Eval pts = number of evaluable patients; G-CSF = granulocyte-colony stimulating factor; GvHD =
graft-versus-host disease; IV = intravenous; Plt = platelet; Proc. Vol = processed blood volume by leukapheresis; SC = subcutaneous.
Fig. 3. Immunologic reconstitution. Numbers of CD3+;
CD3+/CD4+; CD3 + CD8+; CD19+, and NK cells in the
peripheral blood at 3, 6, 12, and 24 months after transplant.
At 12 months: CD3 + cells: median, 0.84 × 109/L (0.33–1.65);
normal range, 0.66–2.10. CD3+/CD4+ cells: median, 0.30 × 109/L
(0.17–0.75); normal range, 0. 32–1.36. CD3+/CD8+ cells: median,
0.45 × 109/L (0.11–1.24); normal range, 0.15–0.88. CD3–/CD16
+/CD56+ NK cells: median, 0.20 × 109/L (0.13–0.52); normal
range, 0.09–0.62. CD19+ cells: median, 0.27 × 109/L (0.09–0.95);
normal range, 0.10–0.5. Each box is drawn from the 25th
percentile to the 75th percentile of the cell counts, and the
horizontal bar within the box indicates the median cell count.
The line up from the top of the box goes to the upper adjacent
value as deﬁned.14 The dots indicate cell counts larger than the
upper adjacent value. [Color ﬁgure can be viewed at
wileyonlinelibrary.com]
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in the PXF-transplanted patients, the numbers of CD19+
cells 12 months after transplantation also seemed higher
compared to G-CSF, but numbers are small. The kinetics
data suggest that mobilization of CD34+ cells starts within
2 hours after administration of SC PXF and continues dur-
ing the apheresis procedure, that is, until 14 hours after
administration of PXF. A recent study showed a similar pat-
tern with 0.240 mg/kg and 0.480 mg/kg of PXF SC.15 Con-
sidering this long period with CD34+ cells present in the
peripheral blood, a large-volume apheresis might be useful
in donors who are mobilized with PXF. This could also
reduce the number of injections.
The use of SC PXF is certainly associated with side
effects in the majority of donors. Diarrhea, vomiting, nau-
sea, and tingling were most frequently reported. However,
these were all Grade 1 to 2 and resolved completely. This is
in agreement with earlier studies with PXF in both patients
and donors.6,7,9 Common Terminology Criteria for Adverse
Events Grade 3 adverse events were reported in 3 of
23 donors: clotting during the leukapheresis, fatigue, and
hypokalemia. Our study included donor follow-up for
2 years and is still running for this part. These results will
be reported. Although the results after SC and IV adminis-
tration formally cannot be compared, we have the impres-
sion that no major differences seem apparent. Although
infusion of PXF and stem cell collection in 1 day seems
attractive, this will mean long hours for donors and collec-
tion centers, especially when large-volume apheresis is per-
formed. Therefore, we would favor the use of SC PXF in
allogeneic donors. Based on the now available data, we con-
sider stem cell mobilization in allogeneic donors with one
or two SC injections with PXF 0.320 mg/kg feasible. Indeed,
stem cell mobilization with PXF is accompanied by side
effects, mainly Grade 1 or 2. On the other hand, this counts
also for the SC administration of 10–12 injections of G-CSF,
with side effects often requiring medication.2 A future pro-
spective randomized study comparing both G-CSF and PXF
SC for stem cell mobilization in adult HLA-identical donors
including cost-effectiveness and quality-of-life studies would
be helpful.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article.
Appendix S1: Mobilization of peripheral blood blood stem
cells with intravenous Plerixafor in allogeneic HLAidentical
sibling donors.
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